OBJECTIVES/HYPOTHESIS: No reliable molecular biomarker is currently available for clinical application in the management of head and neck cancer patients. The AKT/mTOR pathway is activated in 90% to 100% of head and neck squamous cell cancer (HNSCC) and could be promising biomarkers closely linked to cancer incidence. STUDY DESIGN: Retrospective study of HNSCC and non-cancer patients. METHODS: Oral mucosa from noncancer patients were compared to HNSCC tumors and junctional zone mucosa. The candidate biomarkers mTOR, AKT, 4EBP1, and S6 kinase, signaling components upstream and downstream of mTOR that appear dysregulated in HNSCC, were evaluated using immunohistochemistry (IHC) and Western blot analysis. RESULTS: Expression of phosphorylated AKT and phosphorylated mTOR were significantly higher in cancer patient tumors compared to noncancer oral mucosa samples (P = .004 and P = .026, respectively) by Western blot analysis. Expression of p-mTOR and p-4EBP1 were higher in patient junctional zones compared to tumors (p = 0.017 and p = 0.022, respectively) and no difference in p-AKT or p-S6 expression in HNSCC patients' junctional zone compared to tumors. IHC-demonstrated p-mTOR expression was 81.9% sensitive and 100% specific in differentiating cancer from noncancer mucosa, whereas p-4EBP1 expression by IHC was only 50.0% sensitive and 95.5% specific in differentiating normal mucosa from HNSCC (P < .01). CONCLUSIONS: Phosphorylated mTOR appears to be a reliable biomarker by both Western blot analysis (P = .026) and IHC in human head and neck cancer (P < .001). Moreover, phosphorylated AKT, which is immediately upstream of mTOR, is a potential biomarker that should be further studied. Clinical trials with mTOR inhibitors are being evaluated for HNSCC, and selecting patients that are likely to respond to these inhibitors requires identifying and validating predictive biomarkers of response.
OBJECTIVES/HYPOTHESIS: No reliable molecular biomarker is currently available for clinical application in the management of head and neck cancerpatients. The AKT/mTOR pathway is activated in 90% to 100% of head and neck squamous cell cancer (HNSCC) and could be promising biomarkers closely linked to cancer incidence. STUDY DESIGN: Retrospective study of HNSCC and non-cancerpatients. METHODS: Oral mucosa from noncancer patients were compared to HNSCC tumors and junctional zone mucosa. The candidate biomarkers mTOR, AKT, 4EBP1, and S6 kinase, signaling components upstream and downstream of mTOR that appear dysregulated in HNSCC, were evaluated using immunohistochemistry (IHC) and Western blot analysis. RESULTS: Expression of phosphorylated AKT and phosphorylated mTOR were significantly higher in cancerpatienttumors compared to noncancer oral mucosa samples (P = .004 and P = .026, respectively) by Western blot analysis. Expression of p-mTOR and p-4EBP1 were higher in patient junctional zones compared to tumors (p = 0.017 and p = 0.022, respectively) and no difference in p-AKT or p-S6 expression in HNSCC patients' junctional zone compared to tumors. IHC-demonstrated p-mTOR expression was 81.9% sensitive and 100% specific in differentiating cancer from noncancer mucosa, whereas p-4EBP1 expression by IHC was only 50.0% sensitive and 95.5% specific in differentiating normal mucosa from HNSCC (P < .01). CONCLUSIONS: Phosphorylated mTOR appears to be a reliable biomarker by both Western blot analysis (P = .026) and IHC in human head and neck cancer (P < .001). Moreover, phosphorylated AKT, which is immediately upstream of mTOR, is a potential biomarker that should be further studied. Clinical trials with mTOR inhibitors are being evaluated for HNSCC, and selecting patients that are likely to respond to these inhibitors requires identifying and validating predictive biomarkers of response.
Authors: Robert E Brown; Ping L Zhang; Mingyue Lun; Shaobo Zhu; Phillip K Pellitteri; Waldemar Riefkohl; Amy Law; G Craig Wood; Thomas L Kennedy Journal: Ann Clin Lab Sci Date: 2006 Impact factor: 1.256
Authors: Cherie-Ann O Nathan; Nazanin Amirghahari; Xiaohua Rong; Tony Giordano; Don Sibley; Mary Nordberg; Jonathan Glass; Anshul Agarwal; Gloria Caldito Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: Alfredo A Molinolo; Stephen M Hewitt; Panomwat Amornphimoltham; Somboon Keelawat; Samraeung Rangdaeng; Abelardo Meneses García; Ana R Raimondi; Rafael Jufe; María Itoiz; Yan Gao; Dhananjaya Saranath; George S Kaleebi; George H Yoo; Lee Leak; Ernest M Myers; Satoru Shintani; David Wong; H Davis Massey; W Andrew Yeudall; Fulvio Lonardo; John Ensley; J Silvio Gutkind Journal: Clin Cancer Res Date: 2007-09-01 Impact factor: 12.531
Authors: Dong Hoon Shin; Hye-Young Min; Adel K El-Naggar; Scott M Lippman; Bonnie Glisson; Ho-Young Lee Journal: Mol Cancer Ther Date: 2011-10-06 Impact factor: 6.261
Authors: Christian Freudlsperger; Jeffrey R Burnett; Jay A Friedman; Vishnu R Kannabiran; Zhong Chen; Carter Van Waes Journal: Expert Opin Ther Targets Date: 2010-11-26 Impact factor: 6.902
Authors: Ali Azimi; Kimberley L Kaufman; Marina Ali; Steven Kossard; Pablo Fernandez-Penas Journal: Cancer Genomics Proteomics Date: 2016 11-12 Impact factor: 4.069
Authors: Justin J Reid; Melissa A Linden; Frederick F Peelor; Richard A Miller; Karyn L Hamilton; Benjamin F Miller Journal: J Gerontol A Biol Sci Med Sci Date: 2020-01-01 Impact factor: 6.053
Authors: J Musa; M F Orth; M Dallmayer; M Baldauf; C Pardo; B Rotblat; T Kirchner; G Leprivier; T G P Grünewald Journal: Oncogene Date: 2016-02-01 Impact factor: 9.867